MTOR and renal cell carcinoma: METTL13 is lowly expressed in renal cell carcinoma, and knockdown of METTL13 promotes the PI3K/AKT/mTOR/HIF-1α pathway leading to migratory ability and invasiveness of renal cell carcinoma cells as well as elevated Vimentin and N-cadherin [56].